Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Echinococcus granulosus | tumor necrosis factor receptor superfamily | 0.019 | 0.4273 | 1 |
Mycobacterium tuberculosis | Possible penicillin-binding protein | 0.0271 | 0.9552 | 0.5 |
Brugia malayi | Pre-SET motif family protein | 0.0244 | 0.78 | 1 |
Echinococcus multilocularis | TNFR CD27 30 40 95 cysteine rich region | 0.019 | 0.4273 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0124 | 0.000000095649 | 0.00000012262 |
Brugia malayi | Death domain containing protein | 0.0124 | 0.000000095649 | 0.00000012262 |
Echinococcus granulosus | Ankyrin | 0.0124 | 0.000000095649 | 0.00000022386 |
Echinococcus multilocularis | Ankyrin | 0.0124 | 0.000000095649 | 0.00000022386 |
Echinococcus granulosus | TNFR CD27 30 40 95 cysteine rich region | 0.019 | 0.4273 | 1 |
Brugia malayi | Uncoordinated protein 44 | 0.0124 | 0.000000095649 | 0.00000012262 |
Echinococcus multilocularis | ankyrin repeat and death domain containing protein | 0.0124 | 0.000000095649 | 0.00000022386 |
Echinococcus granulosus | ankyrin repeat and death domain containing protein | 0.0124 | 0.000000095649 | 0.00000022386 |
Brugia malayi | Protein kinase domain containing protein | 0.0124 | 0.000000095649 | 0.00000012262 |
Schistosoma mansoni | tumor necrosis factor receptor related | 0.019 | 0.4273 | 1 |
Echinococcus multilocularis | tumor necrosis factor receptor superfamily | 0.019 | 0.4273 | 1 |
Loa Loa (eye worm) | pre-SET domain-containing protein family protein | 0.0244 | 0.78 | 1 |
Trichomonas vaginalis | set domain proteins, putative | 0.0277 | 1 | 0.5 |
Schistosoma mansoni | ankyrin 23/unc44 | 0.0124 | 0.000000095649 | 0.00000022386 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Inhibition (functional) | = 2 % | Inhibitory activity against human platelet aggregation at 200 uM | ChEMBL. | 7837229 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.